학술논문
Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1).
Document Type
Article
Author
Fisher, Michael J.; Jones, David T. W.; Li, Yimei; Guo, Xiaofan; Sonawane, Poonam S.; Waanders, Angela J.; Phillips, Joanna J.; Weiss, William A.; Resnick, Adam C.; Gosline, Sara; Banerjee, Jineta; Guinney, Justin; Gnekow, Astrid; Kandels, Daniela; Foreman, Nicholas K.; Korshunov, Andrey; Ryzhova, Marina; Massimi, Luca; Gururangan, Sri; Kieran, Mark W.
Source
Subject
*NEUROFIBROMATOSIS 1
*GLIOMAS
*BRAIN tumors
*DIAGNOSIS
*DNA methylation
*PHARMACOGENOMICS
*
*
*
*
*
Language
ISSN
0001-6322
Abstract
Low-grade gliomas (LGGs) are the most common childhood brain tumor in the general population and in individuals with the Neurofibromatosis type 1 (NF1) cancer predisposition syndrome. Surgical biopsy is rarely performed prior to treatment in the setting of NF1, resulting in a paucity of tumor genomic information. To define the molecular landscape of NF1-associated LGGs (NF1-LGG), we integrated clinical data, histological diagnoses, and multi-level genetic/genomic analyses on 70 individuals from 25 centers worldwide. Whereas, most tumors harbored bi-allelic NF1 inactivation as the only genetic abnormality, 11% had additional mutations. Moreover, tumors classified as non-pilocytic astrocytoma based on DNA methylation analysis were significantly more likely to harbor these additional mutations. The most common secondary alteration was FGFR1 mutation, which conferred an additional growth advantage in multiple complementary experimental murine Nf1 models. Taken together, this comprehensive characterization has important implications for the management of children with NF1-LGG, distinct from their sporadic counterparts. [ABSTRACT FROM AUTHOR]